#steatotic
LightNews LightNews
frezzalab.bsky.social
Congrats @andreamorandi.bsky.social &team

"Estrogen-dependent activation of TRX2 reverses oxidative stress and metabolic dysfunction associated with steatotic disease"
www.nature.com/articles/s41...
Estrogen-dependent activation of TRX2 reverses oxidative stress and metabolic dysfunction associated with steatotic disease - Cell Death & Disease
Cell Death & Disease - Estrogen-dependent activation of TRX2 reverses oxidative stress and metabolic dysfunction associated with steatotic disease
www.nature.com
February 1, 2025 at 8:30 AM
amjhypertension.bsky.social
Chronic infection and metabolic stress: a converging axis driving hypertension and metabolic dysfunction-associated steatotic liver disease outcomes

by Jannis Kountouras et al.
October 2, 2026 at 7:40 AM
natrevgastrohep.nature.com
Our APRIL ISSUE is live! Steatotic liver disease and alcohol, disorders of gut–brain interaction, coeliac disease, advanced chronic liver disease, and much more!

www.nature.com/nrgastro/vol...
Steatotic liver disease burden paradox, inspired by the Perspective on p281.
March 31, 2025 at 9:16 AM
scinews.bsky.social
Metabolic Dysfunction–Associated Steatotic Liver Disease in Adults
A Review @jama.com

🎯Flowchart Showing the Classification and Subclassification of Steatotic Liver Disease

jamanetwork.com/journals/jam...
November 17, 2025 at 4:09 AM
natbiotech.nature.com
AAV capsid prioritization in normal and steatotic human livers maintained by machine perfusion - @ucsfsurgery.bsky.social go.nature.com/3PWpD4o
AAV capsid prioritization in normal and steatotic human livers maintained by machine perfusion - Nature Biotechnology
The suitability of different AAV capsids for gene therapy is assessed in human livers.
go.nature.com
January 29, 2025 at 4:17 PM
natrevgastrohep.nature.com
New online! Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment
Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment
Nature Reviews Gastroenterology & Hepatology, Published online: 17 February 2025; doi:10.1038/s41575-025-01045-zThis Review discusses the link between metabolic dysfunction-associated steatotic liver disease (MASLD) — a heterogeneous health condition —…
www.nature.com
February 18, 2025 at 3:44 AM
scinews.bsky.social
🎯Lancet Review Series 2024
@thelancet.bsky.social

Natural history and progression of metabolic dysfunction-associated steatotic liver disease

Image: MASLD progression

Read more
www.thelancet.com/journals/lan...
December 1, 2024 at 4:00 AM
hanseulkim.bsky.social
⚡🦠I'm very excited to share our latest work on the gut microbiome and metabolic dysfunction-associated steatotic liver disease (MASLD) is published in @natmetabolism.nature.com, with @hutlab.bsky.social & @longnguyen.bsky.social!

🔗Check out the paper here:
www.nature.com/articles/s42...
July 3, 2025 at 12:59 PM
thelancet.com
Globally, metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease.

In @lancetgastrohep.bsky.social, a Review summarises recent breakthroughs and potential future developments: spkl.io/63323Aq7BR
Figure summarising the mechanisms of action targeted for MASH therapy. MASH=metabolic dysfunction-associated steatotic liver disease. Copyright: 2025 Elsevier Ltd. All rights are reserved.
January 29, 2026 at 12:05 PM
natrevgastrohep.nature.com
New online! Clusters of metabolic dysfunction-associated steatotic liver disease for precision medicine
Clusters of metabolic dysfunction-associated steatotic liver disease for precision medicine
Nature Reviews Gastroenterology & Hepatology, Published online: 26 February 2025; doi:10.1038/s41575-025-01048-wMetabolic dysfunction-associated steatotic liver disease (MASLD) is a heterogeneous disease regarding its pathophysiology and clinical…
www.nature.com
February 26, 2025 at 10:29 AM
haoyin.bsky.social
Liver-to-Aorta communication😎
#Atheroasclerosis #MAFLD #MedialArterialCalcification

Steatotic Liver-derived #ExtracellularVesicle
⏫atherosclerotic lesion +calcification
⏫MAFLD-associated arterial calcification
⏫Osteogenesis of #SmoothMuscleCell

#AdvSci 2024
onlinelibrary.wiley.com/doi/10.1002/...
January 1, 2025 at 4:13 PM
natureportfolio.nature.com
A phase 3 trial reported in Nature Medicine shows weekly subcutaneous injections of survodutide, a glucagon receptor/GLP-1R dual agonist, lowered liver fat content and body weight in adults with obesity and at-risk metabolic dysfunction-associated steatotic liver disease (MASLD). #medsky 🧪
Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial - Nature Medicine
As presented at the American Diabetes Association Meeting, in this phase 3 trial, weekly subcutaneous injections of survodutide, a glucagon receptor/GLP-1R dual agonist, lowered liver fat content and body weight compared to placebo in adults with obesity and at-risk metabolic dysfunction-associated steatotic liver disease (MASLD).
go.nature.com
June 13, 2026 at 10:40 PM
natmetabolism.nature.com
#Throwback 🧪

REVIEW | Human genetics of steatotic liver disease

@stefano-romeo.bsky.social , R Mancina, L Valenti
Human genetics of steatotic liver disease: insights into insulin resistance and lipid metabolism - Nature Metabolism
This Review summarizes our current knowledge about the genetic underpinnings of metabolic-dysfunction-associated steatotic liver disease and highlights its causal association with type 2 diabetes and insulin resistance.
dlvr.it
February 3, 2026 at 7:02 PM
liverepi.bsky.social
New paper from us in @jhepatology.bsky.social: www.journal-of-hepatology.eu/article/S016...
Causes of death in >13,000 persons with #MASLD - check it out #liversky. So proud of co-senior author Axel Wester and first author medical student Gabriel Issa for the work!
Cause-specific mortality in 13,099 patients with metabolic dysfunction-associated steatotic liver disease in Sweden
Data on cause-specific mortality in metabolic dysfunction-associated steatotic liver disease (MASLD) are limited. We aimed to determine the rate and risk of death from different causes in patients wit...
www.journal-of-hepatology.eu
March 24, 2025 at 7:51 PM
israelsenm.bsky.social
Our newdata show 38% of individuals with SLD are reclassified over 2 years ‼️

Over 60% with MetALD/ALD and 38% with MASLD change subclass.

This highlights that alcohol use and metabolic risk need regular reassessment, incl. for clinical trial eligibility 🧐

Link: www.cghjournal.org/article/S154...
Steatotic liver disease classification is dynamic, affecting clinical trial eligibility and subclass-specific treatments
Steatotic liver disease (SLD) includes the subclasses metabolic-dysfunction associated steatotic liver disease (MASLD), metabolic and alcohol-related liver disease (MetALD) and alcohol-related liver d...
www.cghjournal.org
April 8, 2025 at 6:13 AM
robbrierley.bsky.social
New Review - The liver–brain axis in metabolic dysfunction-associated steatotic liver disease

www.thelancet.com/journals/lan...
Cognitive functions that might be affected in patients with MASLD
December 17, 2024 at 7:07 AM
lancetgastrohep.bsky.social
New Review - Screening for advanced steatotic liver disease

www.thelancet.com/journals/lan...

#LiverSky #MedSky @aleksanderkrag.bsky.social
Screening for advanced steatotic liver disease
Steatotic liver disease often progresses asymptomatically, with the risk of advancing to cirrhosis and liver cancer. Early detection of advanced liver disease through screening presents an opportunity...
www.thelancet.com
July 16, 2025 at 6:09 AM
scinews.bsky.social
Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment. #TIC2025

Free download
www.thelancet.com/journals/lan...
Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment
The global epidemic of metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing worldwide. People with MASLD can progress to cirrhosis and hepatocellular carcinoma and are at inc...
www.thelancet.com
June 16, 2025 at 5:04 AM
natmetabolism.nature.com
#Throwback 🧪
REVIEW | Human genetics of steatotic liver disease

@stefano-romeo.bsky.social , R Mancina, L Valenti
Human genetics of steatotic liver disease: insights into insulin resistance and lipid metabolism - Nature Metabolism
This Review summarizes our current knowledge about the genetic underpinnings of metabolic-dysfunction-associated steatotic liver disease and highlights its causal association with type 2 diabetes and insulin resistance.
dlvr.it
July 6, 2026 at 7:02 PM
natmetabolism.nature.com
REVIEW | R Mancina, L Valenti, @stefano-romeo.bsky.social (U Rome, U Milan, U Gothenburg):

The genetic underpinnings of MASLD and causal associations with T2D and insulin resistance. 🧪
Human genetics of steatotic liver disease: insights into insulin resistance and lipid metabolism - Nature Metabolism
This Review summarizes our current knowledge about the genetic underpinnings of metabolic-dysfunction-associated steatotic liver disease and highlights its causal association with type 2 diabetes and insulin resistance.
bit.ly
November 25, 2025 at 8:01 PM
epigenometech.bsky.social
Epigenetics Update - Multi-modal analysis of human hepatic stellate cells identifies novel therapeutic targets for metabolic dysfunction-associated steatotic liver disease bit.ly/4jHYO0D

#Epigenetics #LiverDisease
---

Gain deeper insights into gene regulation with epigenometech.com
Multi-modal analysis of human hepatic stellate cells identifies novel therapeutic targets for metabolic dysfunction-associated steatotic liver disease
Metabolic dysfunction-associated steatotic liver disease ranges from metabolic dysfunction-associated steatotic liver (MASL) to metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis. T...
bit.ly
April 21, 2025 at 5:05 PM
johnrpetrie.bsky.social
www.ncbi.nlm.nih.gov/pubmed/39488... Lancet review
Steatotic liver disease - PubMed
Steatotic liver disease is the overarching term for conditions characterised by abnormal lipid accumulation in the liver (liver or hepatic steatosis). Steatotic liver disease encompasses what was prev...
www.ncbi.nlm.nih.gov
December 4, 2024 at 5:27 PM
andreamorandi.bsky.social
🚨 📣 Our latest study out in @springernature.com 𝘊𝘦𝘭𝘭 𝘋𝘦𝘢𝘵𝘩 & 𝘋𝘪𝘴𝘦𝘢𝘴𝘦, takes us beyond our usual cancer research comfort zone to explore how #estrogen influences the progression of #MASLD. Well done to @alfredo95.bsky.social and the rest of the team! 🙏

www.nature.com/articles/s41...
Estrogen-dependent activation of TRX2 reverses oxidative stress and metabolic dysfunction associated with steatotic disease - Cell Death & Disease
Cell Death & Disease - Estrogen-dependent activation of TRX2 reverses oxidative stress and metabolic dysfunction associated with steatotic disease
www.nature.com
January 31, 2025 at 4:33 PM
haoyin.bsky.social
My continued biomedical education
#MASLD #MASH

Pathophysiological underpinnings of metabolic dysfunction-associated steatotic liver disease

Gut (microbiota)-liver axis

#HepaticStellateCell #Pericyte #YAP/TAZ #GLutaminolysis #Fibrosis

#AJPCellPhys 2025
journals.physiology.org/doi/abs/10.1...
April 19, 2025 at 7:08 PM
thelancet.com
Globally, metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease.

In @lancetgastrohep.bsky.social, a new Review summarises recent breakthroughs and potential future developments: spkl.io/63326Amv4o
Figure summarising the mechanisms of action targeted for MASH therapy. MASH=metabolic dysfunction-associated steatotic liver disease. Copyright: 2025 Elsevier Ltd. All rights are reserved.
January 8, 2026 at 12:36 PM